PMID- 15603879
OWN - NLM
STAT- MEDLINE
DCOM- 20050331
LR  - 20141120
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 65
IP  - 12
DP  - 2004 Dec
TI  - The contribution of HLA class I antigens in immune status following two doses of 
      rubella vaccination.
PG  - 1506-15
AB  - The variability of humoral and cellular immune responses modulated by human 
      leukocyte antigen (HLA) genes is a significant factor in the protective effect of 
      rubella vaccines. We performed HLA class I typing in a group of 346 healthy 
      schoolchildren and young adults who previously received two doses of 
      measles-mumps-rubella-II vaccine. Rubella virus-specific humoral (serum antibody) 
      immunity and cell-mediated immunity (lymphocyte proliferation) were assessed. 
      Median values for antibody levels and stimulation indices (SI) were 38.63 IU/ml 
      and 2.29 IU/ml, respectively. The alleles that provided suggestive, but not 
      conclusive, evidence of HLA association with rubella seropositivity were 
      HLA-B*2705 (median, 24.68 IU/ml; p = 0.160), B*4501 (median, 61.22 IU/ml; p = 
      0.098), Cw*0303 (median, 30.34 IU/ml; p = 0.102) and Cw*0704 (median, 26.58 
      IU/ml; p = 0.144). These alleles approach, but do not achieve, statistical 
      significance. Of all the alleles analyzed, HLA-B*3503 (median SI, 3.00; p = 
      0.031) and HLA-Cw*1502 (median SI, 3.19; p = 0.035) were positively associated 
      with lymphoproliferative responses to rubella virus antigens, whereas the 
      HLA-B*3901 (SI, 1.34; p = 0.066) allele was negatively associated. This suggests 
      that class I HLA alleles may have limited associations with humoral and cellular 
      immune responses to rubella vaccine. These data may facilitate our understanding 
      of immune response variation in a genetically outbred heterogeneous population.
FAU - Ovsyannikova, Inna G
AU  - Ovsyannikova IG
AD  - Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, Minnesota 
      55905, USA.
FAU - Jacobson, Robert M
AU  - Jacobson RM
FAU - Vierkant, Robert A
AU  - Vierkant RA
FAU - Jacobsen, Steven J
AU  - Jacobsen SJ
FAU - Pankratz, V Shane
AU  - Pankratz VS
FAU - Poland, Gregory A
AU  - Poland GA
LA  - eng
GR  - AI 33144/AI/NIAID NIH HHS/United States
GR  - AI 48793/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Antibodies, Viral)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (Rubella Vaccine)
SB  - IM
MH  - Adolescent
MH  - Alleles
MH  - Antibodies, Viral/blood
MH  - Child
MH  - Female
MH  - Genes, MHC Class I
MH  - HLA-A Antigens/genetics
MH  - HLA-B Antigens/genetics
MH  - HLA-C Antigens/genetics
MH  - *Histocompatibility Antigens Class I
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunity, Cellular
MH  - In Vitro Techniques
MH  - Lymphocyte Activation
MH  - Male
MH  - Measles-Mumps-Rubella Vaccine/administration & dosage/immunology
MH  - Rubella Vaccine/*administration & dosage/*immunology
MH  - Rubella virus/immunology
EDAT- 2004/12/18 09:00
MHDA- 2005/04/01 09:00
CRDT- 2004/12/18 09:00
PHST- 2004/03/29 00:00 [received]
PHST- 2004/07/01 00:00 [revised]
PHST- 2004/07/02 00:00 [accepted]
PHST- 2004/12/18 09:00 [pubmed]
PHST- 2005/04/01 09:00 [medline]
PHST- 2004/12/18 09:00 [entrez]
AID - S0198-8859(04)00156-9 [pii]
AID - 10.1016/j.humimm.2004.07.001 [doi]
PST - ppublish
SO  - Hum Immunol. 2004 Dec;65(12):1506-15. doi: 10.1016/j.humimm.2004.07.001.